Abstract

Current treatments for surgical site infections that are caused by fungi or bacteria with antibiotics and antifungal agents are usually based on the prolonged intravenous administration or use of polymethyl methacrylate cements after removing the prosthesis and cleaning the surrounding tissue, which requires another surgical procedure. However, an administration system that avoids high body exposure to the antimicrobial agent and prevents the patient from having to undergo a new surgery would be more desirable. The present invention discloses 3D printed implants with biocompatible and biodegradable polymers comprising medicinal drugs with immediate-sustained release, having a reduced haemolytic profile, which easily adhere to the prostheses, exhibit a good in vitro efficacy profile against different fungal and bacterial strains and can be sterilised by means of UV light due to the thinness thereof.

IPC Classes  ?

• A61B 17/56 - Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor

Abstract

Provided herein are methods for in-vivo assessment of intraventricular flow shear stress, risk of hemolysis, also the location and extent of blood flow stasis regions and inside a cardiac chamber or blood vessel. Also provided herein are systems for performing such methods. Also provided herein are methods for assessing hemolysis and/or thrombosis risk in patients implanted with an LVAD. LVAD positioning and/or speed may be adjusted based on the results obtained by using methods described herein, and the risk for hemolysis and/or thrombosis can be minimized.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
• A61M 60/857 - Implantable blood tubes
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/026 - Measuring blood flow
• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 8/06 - Measuring blood flow
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings

Abstract

The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.

IPC Classes  ?

• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to imaging probes, preferably radioactive compounds, (also referred to in the present invention as radiotracers) comprising a protein, preferably selected from the list consisting of collagen, fibronectin, and fibrinogen. In a particular embodiment, said protein is covalently bonded to a chelating agent and a radioisotope coordinated to the chelating agent. The present invention also relates to the method of preparation of the compounds and the use of the compounds for the non-invasive detection of infection sites caused by Gram+ bacteria by means of imaging techniques, such as nuclear imaging.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 103/10 - Technetium; Rhenium

Abstract

The present invention relates to a retention and anaesthesia set for the venous access of rodents, which ensures the constant and effective supply of an anaesthetic gas, while the tail remains outside so that the user can easily access the vein of the tail and inject it with a substance. The set comprises a transparent tube (2) comprising a body (6) inside which there is a central through-cavity (3) intended to partially house the rodent, which has at the ends thereof a front opening (4) intended to be connected to an anaesthetic gas tube (25) and a rear opening (5) opposite the front opening (4), and a cap (8) that can be attached to the rear opening (5) and is provided with a central through-hole (17) intended to facilitate the passage and fixation of the tail (1) of the rodent in an assembly situation.

IPC Classes  ?

• A61D 7/04 - Devices for anaesthetising animals by gases or vapours; Inhaling devices
• A61D 3/00 - Appliances for supporting or fettering animals for operative purposes 

Abstract

Provided herein are methods for in-vivo assessment of intraventricular flow shear stress, risk of hemolysis, also the location and extent of blood flow stasis regions and inside a cardiac chamber or blood vessel. Also provided herein are systems for performing such methods. Also provided herein are methods for assessing hemolysis and/or thrombosis risk in patients implanted with an LVAD. LVAD positioning and/or speed may be adjusted based on the results obtained by using methods described herein, and the risk for hemolysis and/or thrombosis can be minimized.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
• A61M 60/857 - Implantable blood tubes
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/026 - Measuring blood flow
• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 8/06 - Measuring blood flow
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings

Abstract

The present disclosure provides methods for in-vivo assessment of the location and extent of blood flow stasis regions inside a cardiac chamber or blood vessel and systems for performing the methods. The disclosure provides methods for assessing risk of intracardiac or intravascular thrombus or of embolism originating in a cardiac chamber or vessel, and methods for assessing the need for and/or optimization of cardiac resynchronization therapy.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/029 - Measuring blood output from the heart, e.g. minute volume
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/026 - Measuring blood flow
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 8/06 - Measuring blood flow

Goods & Services

Pharmaceutical preparations; Regulatory agents of the immune system for medical purposes. Technological and scientific research on cell population separation; Providing of information and data relating to medical research and development. Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Immunological analysis; Development of medical therapies aimed at controlling and modulating the immune system; Cell therapy.

Abstract

The present invention relates to the treatment of sepsis and sepsis-associated acute kidney injury (SA-AKI). More specifically, it relates to cilastatin for use in a method of treating sepsis and/or SA-AKI and reducing its associated mortality, in a mammalian subject. It is further directed to methods for treating sepsis and/or SA-AKI; and to pharmaceutical compositions for use in the methods of the invention.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are methods for in-vivo assessment of intraventricular flow shear stress, risk of hemolysis, also the location and extent of blood flow stasis regions and inside a cardiac chamber or blood vessel. Also provided herein are systems for performing such methods. Also provided herein are methods for assessing hemolysis and/or thrombosis risk in patients implanted with an LVAD. LVAD positioning and/or speed may be adjusted based on the results obtained by using methods described herein, and the risk for hemolysis and/or thrombosis can be minimized.

IPC Classes  ?

• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/026 - Measuring blood flow
• A61B 8/06 - Measuring blood flow

Abstract

The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.

IPC Classes  ?

• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

in vitroex vivo ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.

IPC Classes  ?

• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

The present invention relates to a system (1) and method for the automatic, real-time detection of anomalous electrophysiological patterns, such as circular- and rotational-activation patterns, from electrophysiological signals captured by at least one first set of electrodes, such as a multi-electrode catheter, from which signals is generated an electrophysiological activation pattern that is compared to at least one pre-established electrophysiological activation pattern to detect activation nodes and generate a warning signal when same are detected.

IPC Classes  ?

• A61B 5/046 - Detecting fibrillation

Abstract

The invention relates to a device and method for generating tomograms. By means of the combination of the device and method, results equivalent to those obtained with traditional CAT systems can be obtained, using very few projections obtained in a limited angular range of movement of a source–detector assembly and/or elevated mechanical tolerance in the positioning of the source and detector. The device comprises: an X-ray imaging device with an assembly comprising an X-ray source (1) and an X-ray detector (2), with movement; a surface scanning device (4); and a data control and processing system configured to execute at least one calibration routine and one specific tomogram generation routine that uses data obtained by the X-ray imaging device and the surface scanning device to refine the geometric calibration according to the current trajectory and obtain a clinical-quality tomographic image (suitable for clinical diagnosis).

IPC Classes  ?

• A61B 6/03 - Computerised tomographs
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G06T 11/00 - 2D [Two Dimensional] image generation
• A61B 6/02 - Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis

Abstract

The device for locating cardiac arrhythmias comprises a three-dimensional reconstruction of the patient's torso and a number of surface electrodes, wherein the three-dimensional reconstruction of the patient's torso is generated through a number of images obtained by means of at least one camera. In particular, the device comprises elements for locating the surface electrodes, which detect the position of the electrodes with respect to the patient's torso, and data processing elements that generate, on the basis of the three-dimensional reconstruction and the position of the electrodes, a surface electrocardiographic map, and said surface electrocardiographic map has a number of data corresponding to readings of the surface electrodes related to areas of the three-dimensional reconstruction.

IPC Classes  ?

• A61B 5/361 - Detecting fibrillation
• G06T 17/00 - 3D modelling for computer graphics
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• A61B 5/25 - Bioelectric electrodes therefor
• A61B 5/282 - Holders for multiple electrodes
• A61B 5/316 - Modalities, i.e. specific diagnostic methods
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/287 - Holders for multiple electrodes, e.g. electrode catheters for electrophysiological study [EPS]
• A61B 18/14 - Probes or electrodes therefor

Abstract

The present invention relates to the treatment of sepsis and sepsis-associated acute kidney injury (SA-AKI). More specifically, it relates to cilastatin for use in a method of treating sepsis and/or SA-AKI and reducing its associated mortality, in a mammalian subject. It is further directed to methods for treating sepsis and/or SA-AKI; and to pharmaceutical compositions for use in the methods of the invention.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to the treatment of sepsis and sepsis-associated acute kidney injury (SA-AKI). More specifically, it relates to cilastatin for use in a method of treating sepsis and/or SA-AKI and reducing its associated mortality, in a mammalian subject. It is further directed to methods for treating sepsis and/or SA-AKI; and to pharmaceutical compositions for use in the methods of the invention.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present disclosure provides methods for in-vivo assessment of the location and extent of blood flow stasis regions inside a cardiac chamber or blood vessel and systems for performing the methods. The disclosure provides methods for assessing risk of intracardiac or intravascular thrombus or of embolism originating in a cardiac chamber or vessel, and methods for assessing the need for and/or optimization of cardiac resynchronization therapy.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/029 - Measuring blood output from the heart, e.g. minute volume
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/026 - Measuring blood flow
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 8/06 - Measuring blood flow

Abstract

The invention relates to a mouth protector device with a tongue depressor, comprising a first cover (1) for protecting the lip and the teeth of the upper jaw and a second cover (2) for protecting the lip and the teeth of the lower jaw, both covers being connected and articulated in relation to each other by means of an opening and locking regulator (3) which holds the mouth of the patient open for the introduction of exploration or operating instruments through the oral cavity, wherein the second cover (2) has a continuous groove (4) for the insertion of a semi-rigid tongue depressor (5) which depresses and holds back the tongue. The first (1) and second (2) covers also comprise side extensions (6) for protecting the row of premolars and molars and at least one tape (7) for connecting the rear ends thereof, said tape passing around the rear part of the head of the patient, in order to provide the device with increased stability.

IPC Classes  ?

• A61B 1/24 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressors; Instruments for opening or keeping open the mouth
• A61B 13/00 - Instruments for depressing the tongue
• A61B 17/94 - Endoscopic surgical instruments

Abstract

The invention relates to metal nanoparticles, preferably gold and silver, stabilised with dendrons, having a carbosilane structure and functionalised on the periphery thereof with anionic or cationic groups that provide the nanoparticle with a negative or positive net charge, respectively. These nanoparticles have been synthesised by reduction of a metal precursor in the presence of dendritic wedges or by substitution of ligands already present in metal nanoparticles by carbosilane dendrons. The invention also relates to the method for the production thereof and to the uses thereof in biomedicine.

IPC Classes  ?

• C07F 7/08 - Compounds having one or more C—Si linkages
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 33/00 - Antiparasitic agents
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07F 1/10 - Silver compounds
• C07F 1/12 - Gold compounds

Abstract

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/282 - Platinum compounds
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/02 - Halogenated hydrocarbons
• A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 49/04 - X-ray contrast preparations

Abstract

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

IPC Classes  ?

• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/282 - Platinum compounds
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention relates to a device for identifying the site of cardiac arrhythmias, comprising a three-dimensional reconstruction (4) of the chest of a patient and a series of surface electrodes (2) wherein the three-dimensional reconstruction (4) of the chest of the patient is generated by means of a series of images (1) obtained by means of at least one camera. The device especially comprises means for identifying the position of the surface electrodes (2), which detect the position of the electrodes in relation to the chest of the patient, and data processing means that use the three-dimensional reconstruction (4) and the position of the electrodes to generate an electrocardiographic surface map (7), said electrocardiographic surface map (7) comprising a series of data corresponding to readings of the surface electrodes (2) associated with areas of the three-dimensional reconstruction (4).

IPC Classes  ?

• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/0408 - Electrodes specially adapted therefor
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G06T 17/00 - 3D modelling for computer graphics

Abstract

The present invention relates to a catheter and method for detecting electrical activity in an organ. The catheter comprises: a proximal end with means for connecting to a signal processing system; and a distal end for inserting into a patient's organ, there being at least 3 arms extending from the distal end, each arm comprising at least one electrode. The catheter further comprises a central electrode at the distal end of the catheter. The method comprises: inserting a multi-electrode catheter into a patient's organ; obtaining and conditioning a signal corresponding to the positioning of the electrodes; obtaining causal information concerning the current site; processing and summarising the causal information obtained together with causal information concerning previous sites; visually presenting a recurrence plot of all the causal information obtained; and then moving the catheter to a new site and repeating the method until a complete recurrence plot is obtained.

IPC Classes  ?

• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/042 - Electrodes specially adapted therefor for introducing into the body

Abstract

This invention describes a method, the starting point of which is a three-dimensional image of the heart. A region of interest is defined on said image. Moreover, the surface which will be represented in the display in the form of a three-dimensional polygon mesh is defined. Each vertex of the mesh is associated with a function which assigns weights to each element in the region of interest. Display parameters are assigned to the vertices using said functions together with the intensity values of the elements in the region of interest. Said parameters are used to generate the interactive display of the surface. One application of the method would be the use thereof to help to characterize the myocardial substrate of ventricular tachycardia in patients with ischemic heart disease and to guide ablation procedures for correcting said tachycardia.

IPC Classes  ?

• G06T 15/00 - 3D [Three Dimensional] image rendering
• G06T 17/00 - 3D modelling for computer graphics
• A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)

Abstract

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

IPC Classes  ?

• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/282 - Platinum compounds
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Method for detecting and differentiating valid events in gamma radiation detectors (505, 510), which method comprises the following steps of: obtaining a timing pulse from the detector (505, 510) in which an event is detected; comparing the timing pulse obtained with two thresholds (U1, U2), thus generating two digital comparison pulses, the input edges of which correspond to the instants at which the timing pulse exceeds said thresholds (U1, U2); combining the two digital comparison pulses such that a digital window pulse is generated, the duration of which is Tpulse =TA ± TB, where TA is a fixed value and TB is the interval of time which has elapsed between the respective input edges of the digital comparison pulses; and determining whether the event is valid as a function of the digital window pulse obtained.

IPC Classes  ?

• G01T 1/17 - Circuit arrangements not adapted to a particular type of detector

Abstract

The invention relates to an improved method for assessing cardiovascular risk, which can be used to refine the risk of a person experiencing a cardiovascular event, initially determined by means of classification according to risk group, using a method that takes account of conventional cardiovascular risk factors, such as the European Societies' cardiovascular risk chart. The method takes account of the potential influence on cardiovascular risk variations of total homocysteine values, intraleukocytic protein Hsp70i and the genotype of the Hsp70-1 gene, allowing risk group reclassification and, if necessary, the establishment of suitable preventive and/or corrective measures in order to prevent a cardiovascular event.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

The invention relates to the use of cilastatin for the preparation of a medicament to reduce the nephrotoxicity of a nephrotoxic compound penetrating cells of the proximal tubule through cholesterol rafts. It is based on the discovery that a large number of nephrotoxic compounds, including drugs, penetrate cells of the proximal tubule through the cholesterol rafts and that cilastatin is capable of interfering in this transport mechanism, reducing to varying degrees the nephrotoxicity of said compounds. The nephroprotective effect is common to compounds of differing chemical nature and solubility and is specific for the kidney, not interfering with the effects of nephrotoxic drugs the targets whereof lie in other organs. Consequently, administration of cilastatin permits reduction in nephrotoxic effects of differing drugs without reducing the therapeutic effect thereof.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 49/04 - X-ray contrast preparations
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/282 - Platinum compounds
• A61P 13/00 - Drugs for disorders of the urinary system

Abstract

The invention relates to a multi-modality tomography apparatus (11) including a first tomograph (13) and a second tomograph or imaging system (14) using different tomography techniques, such as X-ray CT tomography and PET or SPECT tomography, or a tomographic or planar optical imaging system, which are located on the same face of a support means (12) which can rotate in both directions of rotation around an axial support shaft (12), such that a subject undergoing examination and placed on a subject support does not have to be moved during a tomographic examination with any of the two tomographs (13, 14) installed on the same face of the support (12).

IPC Classes  ?

• G01N 23/083 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and measuring the absorption the radiation being X-rays
• H05G 1/70 - Circuit arrangements for X-ray tubes with more than one anode; Circuit arrangements for apparatus comprising more than one X-ray tube
• G01T 1/00 - Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation

Abstract

The invention relates to an incubator for imaging with non-ionising radiation, designed for newborn care, including a projective or tomographic imaging system, or both simultaneously, which uses non-ionizing radiation in the band of the electromagnetic spectrum included between ultraviolet light and far infrared. Said system can be used to view a subject (11) located in the incubator (19) such that said projective or tomographic image can be morphological or functional.

IPC Classes  ?

• A61G 11/00 - Baby-incubators; Couveuses

Abstract

Haemodialfiltration apparatus comprising a haemofilter (11) with a membrane, a first circuit for a dialysis solution with a syringe-type liquid pump (20) and valves located upstream (19, 21) and downstream (18) from the haemofilter (11) and a second circuit for blood with a blood pump (15) and valves located upstream (14, 16) and downstream (17) from the haemofilter (11). Haemodialfiltration method comprising in each cycle reversing the filtration direction in the membrane of the haemofilter (11) by means of the coordinated operation of the pumps (15, 20) and the valves (14,16- 19,21) controlled by a control unit, in such a way that after filtering and washing of a predetermined volume of blood plasma, an equivalent volume of replacement fluid is filtered towards the blood flow and within the haemofilter (11) for the blood to recover its original haemocrit and to minimize coagulation risks.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration

Abstract

The invention relates to a multi-modality tomography apparatus (11) including a first tomograph and a second (14) tomograph or image system using different tomography techniques, such as X-ray CT tomography and PET or SPECT tomography, or a tomographic or planar optical image system which are housed on the same surface of a support means (12) which can rotate in both directions of rotation around an axial support shaft (12), such that a patient undergoing examination on a patient support does not have to be moved during a tomographic examination with any of the two tomographs (13, 14) installed on the same face of the support (12).

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment

Abstract

The invention relates to an endothelized artificial matrix comprising a fibrin gel, which is a superproducer of proantiogenic factors. The inventive matrix comprises a fibrin gel containing embedded endothelial cells which have been transfected in vitro with at least one adenoviral vector containing the sequence encoding at least one proangiogenic factor, which is inserted such that it can be overexpressed in said endothelial cells. The insertion of the aforementioned matrix between a flap and the receptor site thereof during a transplant procedure improves the survival rates of said flap, since the endothelized matrix can induce angiogenesis both in the flap and in the receptor site and, in this way, improve the vascularization of the transplanted area.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/18 - Growth hormones
• A61F 2/10 - Hair or skin implants
• A61L 27/60 - Materials for use in artificial skin